Influencing Immunity: Role of Extracellular Vesicles in Tumor Immune Checkpoint Dynamics

Overview

Journal Exp Mol Med

Specialties Biochemistry
Molecular Biology

Date 2024 Nov 11

PMID 39528800

Authors

Ziyang Ye

Genpeng Li

Jianyong Lei

Affiliations

Soon will be listed here.

Abstract

Immune checkpoint proteins (ICPs) serve as critical regulators of the immune system, ensuring protection against damage due to overly activated immune responses. However, within the tumor environment, excessive ICP activation weakens antitumor immunity. Despite the development of numerous immune checkpoint blockade (ICB) drugs in recent years, their broad application has been inhibited by uncertainties about their clinical efficacy. A thorough understanding of ICP regulation in the tumor microenvironment is essential for advancing the development of more effective and safer ICB therapies. Extracellular vesicles (EVs), which are pivotal mediators of cell-cell communication, have been extensively studied and found to play key roles in the functionality of ICPs. Nonetheless, a comprehensive review summarizing the current knowledge about the crosstalk between EVs and ICPs in the tumor environment is lacking. In this review, we summarize the interactions between EVs and several widely studied ICPs as well as their potential clinical implications, providing a theoretical basis for further investigation of EV-related ICB therapeutic approaches.

Citing Articles

LCAT in Cancer Biology: Embracing Epigenetic Regulation, Immune Interactions, and Therapeutic Implications.

Gao M, Zhang W, Li X, Li S, Wang W, Han P Int J Mol Sci. 2025; 26(4).

PMID: 40003919 PMC: 11855027. DOI: 10.3390/ijms26041453.

References

Holmgaard R, Zamarin D, Li Y, Gasmi B, Munn D, Allison J . Tumor-Expressed IDO Recruits and Activates MDSCs in a Treg-Dependent Manner. Cell Rep. 2015; 13(2):412-24. PMC: 5013825. DOI: 10.1016/j.celrep.2015.08.077. View

Serrati S, Guida M, Di Fonte R, De Summa S, Strippoli S, Iacobazzi R . Circulating extracellular vesicles expressing PD1 and PD-L1 predict response and mediate resistance to checkpoint inhibitors immunotherapy in metastatic melanoma. Mol Cancer. 2022; 21(1):20. PMC: 8764806. DOI: 10.1186/s12943-021-01490-9. View

Wang Q, Lian G, Sheng S, Xu J, Ye L, Min C . Exosomal lncRNA NEAT1 Inhibits NK-Cell Activity to Promote Multiple Myeloma Cell Immune Escape via an EZH2/PBX1 Axis. Mol Cancer Res. 2023; 22(2):125-136. DOI: 10.1158/1541-7786.MCR-23-0282. View

Ndhlovu L, Lopez-Verges S, Barbour J, Jones R, Jha A, Long B . Tim-3 marks human natural killer cell maturation and suppresses cell-mediated cytotoxicity. Blood. 2012; 119(16):3734-43. PMC: 3335380. DOI: 10.1182/blood-2011-11-392951. View

Cheng Z, Wang L, Wu C, Huang L, Ruan Y, Xue W . Tumor-derived Exosomes Induced M2 Macrophage Polarization and Promoted the Metastasis of Osteosarcoma Cells Through Tim-3. Arch Med Res. 2020; 52(2):200-210. DOI: 10.1016/j.arcmed.2020.10.018. View

Li X, Wang S, Mu W, Barry J, Han A, Carpenter R . Reactive oxygen species reprogram macrophages to suppress antitumor immune response through the exosomal miR-155-5p/PD-L1 pathway. J Exp Clin Cancer Res. 2022; 41(1):41. PMC: 8793215. DOI: 10.1186/s13046-022-02244-1. View

Im E, Lee C, Moon P, Rangaswamy G, Lee B, Lee J . Sulfisoxazole inhibits the secretion of small extracellular vesicles by targeting the endothelin receptor A. Nat Commun. 2019; 10(1):1387. PMC: 6437193. DOI: 10.1038/s41467-019-09387-4. View

Zhao L, Pei R, Ding Y, Su Z, Li D, Zhu S . LOXL4 Shuttled by Tumor Cells-derived Extracellular Vesicles Promotes Immune Escape in Hepatocellular Carcinoma by Activating the STAT1/PD-L1 Axis. J Immunother. 2023; 47(2):64-76. DOI: 10.1097/CJI.0000000000000496. View

Fan Z, Weng Q, Li Y, Zeng T, Wang J, Zhang H . Accurate and rapid quantification of PD-L1 positive exosomes by a triple-helix molecular probe. Anal Chim Acta. 2023; 1251:340984. DOI: 10.1016/j.aca.2023.340984. View

10.

Yuan Y, Jiao P, Wang Z, Chen M, Du H, Xu L . Endoplasmic reticulum stress promotes the release of exosomal PD-L1 from head and neck cancer cells and facilitates M2 macrophage polarization. Cell Commun Signal. 2022; 20(1):12. PMC: 8796490. DOI: 10.1186/s12964-021-00810-2. View

11.

Burova E, Hermann A, Dai J, Ullman E, Halasz G, Potocky T . Preclinical Development of the Anti-LAG-3 Antibody REGN3767: Characterization and Activity in Combination with the Anti-PD-1 Antibody Cemiplimab in Human -Knockin Mice. Mol Cancer Ther. 2019; 18(11):2051-2062. DOI: 10.1158/1535-7163.MCT-18-1376. View

12.

Yang Y, Li C, Chan L, Wei Y, Hsu J, Xia W . Exosomal PD-L1 harbors active defense function to suppress T cell killing of breast cancer cells and promote tumor growth. Cell Res. 2018; 28(8):862-864. PMC: 6082826. DOI: 10.1038/s41422-018-0060-4. View

13.

Fan X, Wang J, Qin T, Zhang Y, Liu W, Jiang K . Exosome miR-27a-3p secreted from adipocytes targets ICOS to promote antitumor immunity in lung adenocarcinoma. Thorac Cancer. 2020; 11(6):1453-1464. PMC: 7262893. DOI: 10.1111/1759-7714.13411. View

14.

Akhtar M, Rashid S, Al-Bozom I . PD-L1 immunostaining: what pathologists need to know. Diagn Pathol. 2021; 16(1):94. PMC: 8543866. DOI: 10.1186/s13000-021-01151-x. View

15.

Deng J, Ke H . Overcoming the resistance of hepatocellular carcinoma to PD-1/PD-L1 inhibitor and the resultant immunosuppression by CD38 siRNA-loaded extracellular vesicles. Oncoimmunology. 2023; 12(1):2152635. PMC: 9809939. DOI: 10.1080/2162402X.2022.2152635. View

16.

Guo S, Huang J, Li G, Chen W, Li Z, Lei J . The role of extracellular vesicles in circulating tumor cell-mediated distant metastasis. Mol Cancer. 2023; 22(1):193. PMC: 10688140. DOI: 10.1186/s12943-023-01909-5. View

17.

Liu J, Peng X, Yang S, Li X, Huang M, Wei S . Extracellular vesicle PD-L1 in reshaping tumor immune microenvironment: biological function and potential therapy strategies. Cell Commun Signal. 2022; 20(1):14. PMC: 8796536. DOI: 10.1186/s12964-021-00816-w. View

18.

Affolter A, Liebel K, Tengler L, Seiz E, Tiedtke M, Azhakesan A . Modulation of PD‑L1 expression by standard therapy in head and neck cancer cell lines and exosomes. Int J Oncol. 2023; 63(3). PMC: 10552694. DOI: 10.3892/ijo.2023.5550. View

19.

Gong B, Kiyotani K, Sakata S, Nagano S, Kumehara S, Baba S . Secreted PD-L1 variants mediate resistance to PD-L1 blockade therapy in non-small cell lung cancer. J Exp Med. 2019; 216(4):982-1000. PMC: 6446862. DOI: 10.1084/jem.20180870. View

20.

Oyewole-Said D, Konduri V, Vazquez-Perez J, Weldon S, Levitt J, Decker W . Beyond T-Cells: Functional Characterization of CTLA-4 Expression in Immune and Non-Immune Cell Types. Front Immunol. 2021; 11:608024. PMC: 7770141. DOI: 10.3389/fimmu.2020.608024. View